top of page

ASGCT 2026: Tevard Biosciences' suppressor tRNA programs could have the potential to treat genetic diseases more broadly than the way we traditionally think of drug development

  • 3 hours ago
  • 1 min read

Co-Founder and CEO Daniel Fischer describes how Tevard is harnessing tRNA for drug development against muscular dystrophies, cardiomyopathies, and epilepsies. The company could run basket trials and possibly earn flexible labels because these tRNAs are targeting a class of mutations rather than specific genes.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page